A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease

IntroductionLY450139 (semagacestat) inhibits γ-secretase, a key enzyme for generation of amyloid β (Aβ), the peptide deposited in plaques in Alzheimer disease (AD). Previous data have shown that LY450139 lowers plasma Aβ, but has no clear effect on Aβ1-40 or Aβ1-42 levels in cerebrospinal fluid (CSF). By using targeted proteomics techniques, we recently identified several shorter Aβ isoforms, such as Aβ1-16, that in experimental settings increase during γ-secretase inhibitor treatment, and thus may serve as sensitive biochemical indices of the treatment effect. Here, we test the hypothesis that these shorter Aβ isoforms may be biomarkers of γ-secretase inhibitor treatment in clinical trials.MethodsIn a phase II clinical trial, 35 individuals with mild to moderate AD were randomized to placebo (n = 10) or LY450139 (100 mg (n = 15) or 140 mg (n = 10)) and underwent lumbar puncture at baseline and after 14 weeks of treatment. The CSF Aβ isoform pattern was analyzed with immunoprecipitation combined with MALDI-TOF mass spectrometry.ResultsThe CSF levels of Aβ1-14, Aβ1-15, and Aβ1-16 showed a dose-dependent increase by 57% and 74%, 21% and 35%, and 30% and 67%, respectively in the 100-mg and 140-mg treatment groups. Aβ1-40 and Aβ1-42 were unaffected by treatment.ConclusionsCSF Aβ1-14, Aβ1-15, and Aβ1-16 increase during γ-secretase inhibitor treatment in AD, even at doses that do not affect Aβ1-42 or Aβ1-40, probably because of increased substrate availability of the C99 APP stub (APP β-CTF) induced by γ-secretase inhibition. These Aβ isoforms may be novel sensitive biomarkers to monitor the biochemical effect in clinical trials.Trial registrationClinical Trials.gov NCT00244322

[1]  D. Selkoe,et al.  beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. , 1993, The Journal of biological chemistry.

[2]  D. Holtzman,et al.  In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life , 2003, The Journal of Neuroscience.

[3]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[4]  P. Lansbury,et al.  The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. , 1993, Biochemistry.

[5]  C. Southan,et al.  Identification of a novel aspartic protease (Asp 2) as beta-secretase. , 1999, Molecular and cellular neurosciences.

[6]  Anders Wallin,et al.  An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid , 2006, Neuroscience Letters.

[7]  M. Ball,et al.  Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. , 1994, The Journal of biological chemistry.

[8]  K. Blennow,et al.  A novel pathway for amyloid precursor protein processing , 2011, Neurobiology of Aging.

[9]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[10]  Henrik Zetterberg,et al.  Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. , 2007, Journal of proteome research.

[11]  D. Selkoe,et al.  Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity , 1999, Nature.

[12]  B. de Strooper,et al.  1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel γ-Secretase Modulator, Reduces Brain β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity , 2007, Journal of Pharmacology and Experimental Therapeutics.

[13]  David M Holtzman,et al.  Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.

[14]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[15]  T. Golde.  Alzheimer's Research & Therapy , 2009 .

[16]  J. Trojanowski,et al.  Effects of γ-Secretase Inhibition on the Amyloid β Isoform Pattern in a Mouse Model of Alzheimer’s Disease , 2009, Neurodegenerative Diseases.

[17]  C. Masters,et al.  Inhibition of γ‐secretase causes increased secretion of amyloid precursor protein C‐terminal fragments in association with exosomes , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  D. Beher,et al.  Generation of C‐terminally truncated amyloid‐β peptides is dependent on γ‐secretase activity , 2002 .

[19]  F. D. Miller,et al.  Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain , 2000, Journal of neurochemistry.

[20]  Timothy Harrison,et al.  The Novel γ Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) Reduces Amyloid Plaque Deposition without Evidence of Notch-Related Pathology in the Tg2576 Mouse , 2007, Journal of Pharmacology and Experimental Therapeutics.

[21]  Randall J Bateman,et al.  A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system , 2009, Annals of neurology.

[22]  J. Kornhuber,et al.  Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation , 2002, Journal of neurochemistry.

[23]  G. Westmeyer,et al.  Identification of a β-Secretase Activity, Which Truncates Amyloid β-Peptide after Its Presenilin-dependent Generation* , 2003, The Journal of Biological Chemistry.

[24]  A. Fleisher,et al.  Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. , 2008, Archives of neurology.

[25]  A. Nadin,et al.  Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. , 2000, Nature.

[26]  David G. Tew,et al.  Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase , 1999, Molecular and Cellular Neuroscience.

[27]  T. Golde,et al.  γ-Secretase, Evidence for Multiple Proteolytic Activities and Influence of Membrane Positioning of Substrate on Generation of Amyloid β Peptides of Varying Length* , 1999, The Journal of Biological Chemistry.

[28]  E. Mandelkow,et al.  Tau in Alzheimer's disease. , 1998, Trends in cell biology.

[29]  D. Selkoe,et al.  Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. , 2000, Nature cell biology.

[30]  M. Vandermeeren,et al.  The functional γ-secretase inhibitor prevents production of amyloid β 1–34 in human and murine cell lines , 2001, Neuroscience Letters.

[31]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[32]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[33]  K. Blennow,et al.  Aspects of beta-amyloid as a biomarker for Alzheimer's disease. , 2007, Biomarkers in medicine.

[34]  M. Vandermeeren,et al.  The functional gamma-secretase inhibitor prevents production of amyloid beta 1-34 in human and murine cell lines. , 2001, Neuroscience Letters.

[35]  D. Selkoe,et al.  Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1 , 2000, Nature Cell Biology.

[36]  Min Xu,et al.  Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1 , 2000, Nature.

[37]  D. Beher,et al.  Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity. , 2002, Journal of neurochemistry.